Post-transplant maintenance, high risk?


Post-transplant consolidation and maintenance, high risk?

In general, what is your preferred consolidation and/or maintenance regimen, if any, for an otherwise healthy 62-year-old patient with high-risk MM who responds to induction therapy, undergoes ASCT and achieves a CR?

Same patient with VGPR or PR post-ASCT?

 

Alsina M et al. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014;20(8):1183-9. Abstract

Attal M et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1782-91. Abstract

Liu H, McCarthy P. New developments in post-transplant maintenance treatment of multiple myeloma. Semin Oncol 2013;40(5):602-9. Abstract

Neben K et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012;119(4):940-8. Abstract

Nooka AK et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 2014;28(3):690-3. Abstract

Sonneveld P et al. Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma: Extended follow-up of the HOVON-65/GMMG-HD4 trial. Proc ASH 2013;Abstract 404.